文献速递糖尿病肥胖与代谢综合征

胰高血糖素样肽-1受体激动剂与其他降糖药在非酒精性脂肪性肝病合并2型糖尿病患者中的心血管与死亡结局:一项大型人群匹配队列研究

Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.
PubMed 文献 · Diabetologia · 2023-12-20

基于TriNetX数据库的倾向匹配回顾性队列研究,纳入2,835,398例非酒精性脂肪性肝病合并2型糖尿病患者。与SGLT2抑制剂相比,GLP-1RA组新发心力衰竭、MACE、脑血管事件及全因死亡率均无显著差异;与其他二线或三线降糖药相比,GLP-1RA组上述不良心血管事件及全因死亡率更低。

要点

  • 与SGLT2抑制剂相比,GLP-1RA组新发心力衰竭、MACE、脑血管事件及全因死亡率均无显著差异。
  • 与其他二线或三线降糖药相比,GLP-1RA组心力衰竭、MACE、脑血管事件及全因死亡率均更低。
  • 敏感性分析结果与主要分析一致。

核心结论

  • 在非酒精性脂肪性肝病合并2型糖尿病患者中,与二甲双胍或其他二线及三线降糖药相比,GLP-1RA与更低的不良心血管事件发生率及全因死亡率相关。
  • 与SGLT2抑制剂相比,GLP-1RA组不良心血管事件及全因死亡率无显著差异。

研究设计与样本

  • 基于TriNetX数据库的倾向匹配回顾性队列研究,纳入2013年1月1日至2021年12月31日期间新接受降糖药治疗、年龄超过20岁的患者,随访至2022年9月30日。
  • 采用1:1倾向匹配,按年龄、人口学特征、合并症及用药情况将GLP-1RA新使用者与其他降糖药使用者匹配。
  • 研究共纳入2,835,398例非酒精性脂肪性肝病合并2型糖尿病患者。

主要发现

  • 与SGLT2抑制剂组相比,GLP-1RA组新发心力衰竭(HR 0.97;95% CI 0.93, 1.01)、MACE(HR 0.95;95% CI 0.90, 1.01)及脑血管事件(HR 0.99;95% CI 0.94, 1.03)均无显著差异。
  • 与SGLT2抑制剂组相比,GLP-1RA组全因死亡率无显著差异(HR 1.06;95% CI 0.97, 1.15)。
  • 与其他二线或三线降糖药相比,GLP-1RA组心力衰竭(HR 0.88;95% CI 0.85, 0.92)、MACE(HR 0.89;95% CI 0.85, 0.94)、脑血管事件(HR 0.93;95% CI 0.89, 0.96)及全因死亡率(HR 0.70;95% CI 0.66, 0.75)均更低。
  • 敏感性分析结果与主要分析一致。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: We aimed to determine whether the use of glucagon-like peptide-1 receptor agonists (GLP-1RA) in individuals with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus decreases the risk of new-onset adverse cardiovascular events (CVEs) and mortality rate compared with other glucose-lowering drugs in a real setting at a population level. METHODS: We conducted a population-based propensity-matched retrospective cohort study using TriNetX. The cohort comprised patients over 20 years old who were newly treated with glucose-lowering drugs between 1 January 2013 and 31 December 2021, and followed until 30 September 2022. New users of GLP-1RAs were matched based on age, demographics, comorbidities and medication use by using 1:1 propensity matching with other glucose-lowering drugs. The primary outcome was the new onset of adverse CVEs, including heart failure, composite incidence of major adverse cardiovascular events (MACE; defined as unstable angina, myocardial infarction, or coronary artery procedures or surgeries) and composite cerebrovascular events (defined as the first occurrence of stroke, transient ischaemic attack, cerebral infarction, carotid intervention or surgery), and the secondary outcome was all-cause mortality. Cox proportional hazards models were used to estimate HRs. RESULTS: The study involved 2,835,398 patients with both NAFLD and type 2 diabetes. When compared with the sodium-glucose cotransporter 2 (SGLT2) inhibitors group, the GLP-1RAs group showed no evidence of a difference in terms of new-onset heart failure (HR 0.97; 95% CI 0.93, 1.01), MACE (HR 0.95; 95% CI 0.90, 1.01) and cerebrovascular events (HR 0.99; 95% CI 0.94, 1.03). Furthermore, the two groups had no evidence of a difference in mortality rate (HR 1.06; 95% CI 0.97, 1.15). Similar results were observed across sensitivity analyses. Compared with other second- or third-line glucose-lowering medications, the GLP-1RAs demonstrated a lower rate of adverse CVEs, including heart failure (HR 0.88; 95% CI 0.85, 0.92), MACE (HR 0.89; 95% CI 0.85, 0.94), cerebrovascular events (HR 0.93; 95% CI 0.89, 0.96) and all-cause mortality rate (HR 0.70; 95% CI 0.66, 0.75). CONCLUSIONS/INTERPRETATION: In individuals with NAFLD and type 2 diabetes, GLP-1RAs are associated with lower incidences of adverse CVEs and all-cause mortality compared with metformin or other second- and third-line glucose-lowering medications. However, there was no significant difference in adverse CVEs or all-cause mortality when compared with those taking SGLT2 inhibitors.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Krishnan A, Schneider CV, Hadi Y, et al. Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study. Diabetologia. 2023. PMID: 38117293. doi:10.1007/s00125-023-06057-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。